Brain and Acute Leukemia, Cytoplasmic (BAALC) Peptide
-
- Target See all BAALC products
- BAALC (Brain and Acute Leukemia, Cytoplasmic (BAALC))
- Origin
- Human, Mouse
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), BioImaging (BI)
- Characteristics
- BAALC peptide corresponds to 15 amino acids of BAALC.
-
-
- Application Notes
- BAALC Peptide is used for blocking the activity of BAALC antibody . The BAALC antibody ships at 0.5 mg/mL and the BAALC Peptide ships as a 100 μg pellet. When peptide is reconstituted in 200 μLwater, the concentration will be 0.5 mg/mL, identical to that of the antibody. The best starting ratio would be 1:1 (which means molar excess of peptide relative to antibody when identical volumes are mixed). Mix equal volume of peptide and antibody at the required dilution and leave at ambient temperature for 20 minutes. Then incubate and develop in parallel two blots: one with the antibody and one with the antibody which has been pre-absorbed with the provided peptide.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- BAALC peptide is supplied as 100 µg of dried peptide. When the peptide is reconstituted in 200 µL water, the concentration will be 0.5 mg/mL.
- Storage
- -20 °C
- Storage Comment
- Store at -20°C. When reconstituted minimize freezing and thawing.
-
- Target
- BAALC (Brain and Acute Leukemia, Cytoplasmic (BAALC))
- Synonyms
- si:zc215i13.3 Peptide, si:ch211-215i13.3 Peptide, BAALC Peptide, 2810457D07Rik Peptide, BAALC, MAP3K1 and KLF4 binding Peptide, brain and acute leukemia, cytoplasmic Peptide, BAALC Peptide, baalc Peptide, Baalc Peptide
- Gene ID
- 79870
- NCBI Accession
- NP_079088
- OMIM
- 13376200
- UniProt
- Q8WXS3
-